While AI-based retinal imaging predicts CHD risk, links between CHD lesion complexity and retinopathy, and potential benefits of Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors on retinopathy in CHD patients with T2DM, lack sufficient evidence. The gene discussed is SLC5A2; the disease is retinal disorder.